At the federal level, the Trump administration decided not to proceed with a Biden administration proposal to allow Medicare and require Medicaid to cover obesity drugs but recently launched their own obesity drug coverage initiatives to reduce costs and increase access (see Box 1)
Reduced intake on GLP-1 medications is common
Increase frequency of glucose monitoring with changes to: insulin dosage, concomitant drugs, meal pattern, physical activity, and in patients with renal impairment or hepatic impairment or hypoglycemia unawareness
If you measure purely by cost per pound lost, tirzepatide currently offers slightly better value at $107 per pound versus retatrutide at $118 per pound
Because of this higher potency, the dosing for MT-2 is substantially lower
doi: 10.1006/bbrc.2001.5553 54 MayoK